On January 28, 2016, the Food and Drug Administration approved Merck’s Zepatier (elbasvir/grazoprevir) for chronic hepatitis C virus genotype 1 or 4 infection.  The once-daily pill, which may sometimes be prescribed with ribavirin, has cure rates of over 90%!  Zepatier is a break-through therapy and has a list price of $54,600 for 12 weeks of therapy.

We hope this means that ALL hepatitis C drugs will become more affordable, allowing more people access to treatment and cure!